NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
10.99
-1.54 (-12.29%)
At close: Feb 13, 2026, 4:00 PM EST
11.08
+0.09 (0.81%)
After-hours: Feb 13, 2026, 7:59 PM EST
NovoCure Revenue
NovoCure had revenue of $167.20M in the quarter ending September 30, 2025, with 7.81% growth. This brings the company's revenue in the last twelve months to $642.27M, up 11.17% year-over-year. In the year 2024, NovoCure had annual revenue of $605.22M with 18.82% growth.
Revenue (ttm)
$642.27M
Revenue Growth
+11.17%
P/S Ratio
1.89
Revenue / Employee
$431,632
Employees
1,488
Market Cap
1.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.26B |
| Enovis | 2.23B |
| Integra LifeSciences Holdings | 1.64B |
| CONMED | 1.37B |
| Tandem Diabetes Care | 1.01B |
| InMode | 370.50M |
| PROCEPT BioRobotics | 299.91M |
| Axogen | 214.71M |
NVCR News
- 1 day ago - NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching - Seeking Alpha
- 1 day ago - This Biotech Stock Is Jumping 25% After Getting an FDA Boost - Barrons
- 1 day ago - What's Happening With NovoCure Stock? - Forbes
- 2 days ago - Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar - WSJ
- 2 days ago - U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer - Business Wire
- 4 weeks ago - NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update - Business Wire
- 6 weeks ago - NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy - Seeking Alpha